Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie recently completed a clinical study titled ...
TipRanks on MSN
Jazz Pharmaceuticals completes observational study on Vyxeos liposomal in AML treatment
Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Jazz Pharmaceuticals has recently completed a clinical study ...
Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...
In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...
Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...
Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...
Cytogenetic risk doesn't seem to explain the disparity in mortality of Black vs White patients, a study across 10 clinical ...
A draft proposal from the US Treasury would give FinCEN a central role in reviewing AML violations, expanding its role in AML ...
News-Medical.Net on MSN
Black patients with AML experience earlier onset and poorer outcomes
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...
Argenta announced on Friday it will execute a strategic consolidation of its operations within the United States, a move that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback